Generics Makers Lose Bid To Nix Vimpat Patent In AIA Review
The Patent Trial and Appeal Board on Friday denied a petition for inter partes review of a patent covering UCB Inc.'s epilepsy drug Vimpat, rejecting invalidity arguments by Actavis Inc. and...To view the full article, register now.
Already a subscriber? Click here to view full article